Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Good morning, everyone. I'm Andy Berens, senior biotech analyst at Leerink Partners on day 2 of our Global Healthcare Conference in Miami. We're very happy to have with us Incyte. We have Pablo and ...
Throughout the last three months, 13 analysts have evaluated Incyte (NASDAQ:INCY), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below ...
- Zynyz ® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe - The EC approval ...
(RTTNews) - Incyte (INCY) announced that the European Commission has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel, a platinum-based chemotherapy regimen, for the ...
All right. Welcome back to the 46th Annual TD Cowen Healthcare Conference. Really happy to have the next session here with -- I'm Marc Frahm from the biotech team here at TD Cowen, and we're really ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results